Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 15/20 | 0.78 |
| ▸ | DRD2 | P14416 | 15/20 | 0.78 |
| ▸ | DRD4 | P21917 | 8/20 | 0.74 |
| ▸ | HTR1A | P08908 | 2/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.70 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.70 |
| ▸ | DRD1 | P21728 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 1/20 | 0.69 |
| ▸ | HTR2C | P28335 | 1/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10808759 | 0.93 | DRD2 (0.83) | DRD3DRD2DRD4HTR1AADRA1A | |
| SCHEMBL10908587 | 0.91 | DRD2 (0.83) | DRD3DRD2DRD4HTR1AADRA1D | |
| SCHEMBL8980577 | 0.85 | DRD2 (0.75) | DRD3DRD2DRD4 | |
| SCHEMBL14761722 | 0.85 | DRD2 (1.00) | DRD3DRD2DRD4HTR1AADRA1D | |
| SCHEMBL14761605 | 0.84 | DRD2 (0.98) | DRD3DRD2DRD4HTR1AADRA1D | |
| SCHEMBL19580052 | 0.84 | DRD2 (0.81) | DRD3DRD2DRD4HTR1AADRA1D | |
| SCHEMBL1388239 | 0.83 | DRD2 (0.74) | DRD3DRD2DRD4HTR1AHTR2A | |
| SCHEMBL9653369 | 0.82 | DRD3 (0.72) | DRD3DRD2DRD4HTR1AADRA1D | |
| Hydrochloric Acid SCHEMBL8980742 | 0.82 | DRD2 (0.73) | DRD3DRD2DRD4HTR1AHTR2A | |
| SCHEMBL14761584 | 0.82 | DRD2 (0.94) | DRD3DRD2DRD4HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575185-B2 | Compositions, synthesis, and methods of utilizing quinazolinedione derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20100222359-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES | REVIVA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222359-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF UTILIZING QUINAZOLINEDIONE DERIVATIVES | GRIN2D, GRIK5, GRIK4 | DRD3 112/4885DRD2 82/4885DRD4 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.